Germany-based medical device giant Siemens Healthineers AG (ETR: SHL) has released its financial results for the fourth quarter of fiscal 2024, ended September 30, 2024, and the full fiscal year 2024. The company achieved its targets for revenue growth and earnings per share for FY2024, demonstrating resilience amidst challenging market conditions.
FY2024 Highlights and Equipment Book-to-Bill Ratio
Siemens Healthineers reported an excellent equipment book-to-bill ratio of 1.11 for FY2024, with a continued expansion of order backlog. The company recorded a comparable revenue growth of 4.7%, which increases to 5.2% when excluding the rapid COVID-19 antigen-test business. For fiscal year 2025, the company anticipates a comparable revenue growth in the range of 5% to 6% compared to fiscal year 2024.
Q4 Fiscal Year 2024 Performance
The fourth quarter of fiscal year 2024 saw a strong equipment book-to-bill ratio of 1.12 and a comparable revenue growth of 5.6%. Excluding the rapid COVID-19 antigen-test business, this figure rises to 6.5%. Imaging and Advanced Therapies achieved comparable revenue growth of 7.7% and 6.8%, respectively, while Diagnostics reported a comparable revenue growth of 0.6% without the rapid COVID-19 antigen tests. Varian’s comparable revenue increased by 10.5%.- Flcube.com
